Refine by
Clinic Celiacshield Trial Articles & Analysis
1,560 news found
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), an autologous (patient’s own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under Florida’s SB 1768, ...
Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to ...
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM, OTCQB: HMTXF; FSE:2VF0), the leading autologous (patient’s own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
An Abbreviated New Drug Application (ANDA) is an application submitted to the U.S. FDA to demonstrate that a generic drug is equivalent to a previously approved Reference Listed Drug (RLD) in terms of safety, efficacy, and quality. The ANDA contains information used for the review and approval of a generic drug product, and does not typically require preclinical and clinical trial data, but ...
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles announces the launch of its new line of Endotoxin Free Silver Nanoparticles for biomedical research and bioassay development. These highly purified nanoparticles offer exceptional performance and reliability in various research and commercial applications, such as drug delivery, nanosensors, photothermal ...
Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease. Glaucoma is a group of eye conditions that damage the optic nerve, often ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...
Biopharma PEG, a key provider of premium polyethylene glycol (PEG) derivatives, is thrilled to announce a substantial expansion of its large-scale Good Manufacturing Practice (GMP) production capabilities. This strategic move is aimed at addressing the rising global demand for Lipid Nanoparticles (LNPs), which are vital for nucleic acid drug delivery, especially in mRNA-based therapies and ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from ...
Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development. Psychiatric drug development is a crucial aspect of mental health treatment, as it involves the development of medications that can effectively treat ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company’s work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio’s extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to ...
Creative Enzymes, a leading provider of high-quality enzymes and biochemicals, is proud to announce the addition of Semaglutide to its comprehensive product portfolio. This novel glucagon-like peptide-1 (GLP-1) receptor agonist has generated significant excitement within the pharmaceutical and life sciences industries due to its remarkable efficacy in managing type 2 diabetes. Semaglutide ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
Researchers have made some fascinating discoveries about the treatment of migraine. Calcitonin gene-related peptide (CGRP) has long been associated with the development of migraine. Monoclonal antibodies (mAbs) targeting the CGRP pathway, including erenumab, galcanezumab and fremanezumab, have shown promise in clinical trials and real-life studies. Initially, the European Headache Federation ...
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of ...
ByOncoVITA
STEMart, a US-based provider of comprehensive services for all phases of medical device development, is proud to announce the launch of its new Pilot Production Services for the medical device industry. These services allow manufacturers to test and refine their products prior to full-scale production, streamlining the development process of new medical devices and minimizing risk to save time ...
BySTEMart
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. The stock is trading at $2.0050, up $0.8750, gaining +77.0925% on volume of over 8o ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines is one of NASDAQ's top gainers today and the stock is trending on Yahoo Finance, currently trading at $3.8955, up $1.6955 or 77.0682%. The stock had a morning high of $5.47 on volume of over 36 Million/. The Company's CEO, ...
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...